Mycroft brilliantly laid out how Anavex 2-73 promotes cellular health (normalcy, “homeostasis”), in a duel fashion.
Most drugs promote health by affecting or controlling single molecular reaction pathways.
For example, aspirin works by locking onto cyclooxygenase 2 (COX-2), an enzyme involved in pain signal transmission. It chemically disables COX-2 molecules, thereby reducing pain signal transmission.
Anavex 2-73, inside neurons works in remarkable, multiple ways. It facilitates the healthful, multiple roles of the sigma-1 receptor. No other drug has been shown to usefully do this clinically.
CNS diseases need functioning sigma-1 receptors. In youth, sigma-1 chemistry is normal, with normal, healthful neurons. But with age (or other factors), normal neuron chemistry is disrupted.
Primarily, but not uniquely, energy-producing mitochondria become disconnected from rough endoplasmic reticula, where properly-folded enzyme proteins are produced and control normal cell function. In these aberrant conditions, Anavex 2-73 re-connects the mitochondria and endoplasmic reticula. Health-giving enzymes are then again produced.
Essential Ca+ signaling, among other effects, is also restored and enhanced by Anavex 2-73.
Anavex 2-73, by facilitating normal sigma-1 receptor functions, promotes healthful neuron chemistry. Although a bit over-stated, it’s like a diligent mother inside the neuron, keeping all of the chemical children in good order and discipline. She carries a big stick, and doesn’t hesitate to slap things back into order.
All of this is SO different from the many, now-failed Alzheimer’s treatment drug candidates. First, none of them work; and all have single, narrow molecular pathways they are supposed to affect. Smart investors, after doing deep due diligence (attempting to comprehend the unique, broad-spectrum functionality of Anavex drug candidates), should recognize how Anavex is entirely different; that lumping Anavex 2-73 in with all the other failed and proposed Alzheimer’s drug candidates is a gross chemical and investment error. Healthful apples and toxic oranges, as it were.
But, for due diligence, another unique, favorable trait of Anavex 2-73 should be noted.
All of the above would be irrelevant, were Anavex 2-73 to have, as do almost all nerve-acting drugs, severe side effects. Not so with this molecule. After adequate human testing, not a single significant (disqualifying) adverse event was recorded. No strokes. No hemorrhaging. No psychoses. No heart attacks. Just a few mild headaches or upset stomachs and the like. All of which would be usefully tolerated, given the stunning symptomatic relief Anavex 2-73 promises for those with Alzheimer’s.
